Brought to you by 
Roivant acquires a Glaxo Alzheimer’s compound
05 Jan 2021
Executive Summary
Roivant Sciences Ltd., via its wholly owned subsidiary Roivant Neurosciences Ltd., acquired GlaxoSmithKline PLC's Phase II SB742457 (GSK742457), a selective 5-HT6 antagonist for cognitive and other functional defects in neurological diseases. NOTES: Roivant Neurosciences is now called Axovant Sciences Ltd. and SB742457 was renamed RVT101.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- Product Purchase
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com